INFECTIOUS DISEASES
Comprehensive disease testing
Through BioPharma Diagnostics, our partners have access to Mayo Clinic Laboratories’ infectious disease test catalog, including testing for:
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Helicobacter pylori
- Infectious disease pathology
- Vector-borne diseases
- HIV and hepatitis
Our molecular testing methods include:
- Polymerase chain reaction (PCR) testing
- Advanced whole genome microbial sequencing
- Targeted metagenomic sequencing
- Matrix-assisted laser-desorption/ionization-time of flight (MALDI-TOF) mass spectrometry organism identification
In addition to using clinically available testing, BioPharma Diagnostics partners can access infectious disease testing for clinical trials and be among the first to use up-and-coming tests currently in development.
News and updates
The latest
William Morice II, M.D., Ph.D., recently joined the Advisory Board for a webinar discussion on 2024 lab market trends. Dr. Morice covered the current lab market outlook, the priority trends, and opportunities for future growth.
Bobbi Pritt, M.D., discusses how Mayo Clinic Labs’ updated PCR assay for West Nile virus provides increased sensitivity to detect virus RNA in multiple sources, identifies two virus lineages, and confirms diagnosis.
When most of the world was still struggling to understand how COVID-19 would affect their lives, Atria Senior Living took steps to protect their vulnerable residents and staff.
Mayo Clinic Laboratories now offers a noninvasive approach for the molecular detection of H. pylori, with results that include prediction of clarithromycin resistance delivered within 24 hours.
In this month’s Hot Topic, Robin Patel, M.D., discusses Mayo Clinic Laboratories’ new PCR assay for detection of Helicobacter pylori detection and determination of clarithromycin resistance directly from stool.
Thank you to our staff at Mayo Clinic who step up daily during this time of need to provide access to testing during the global pandemic. We appreciate each one of you and all the sacrifices you personally have made throughout this past year.
A small but in-depth study conducted a postmortem evaluation of the heart tissue of 15 patients with COVID-19, including the first postmortem cardiac findings of three patients who had cleared the virus.
Joshua Bornhorst, Ph.D., associate director of Mayo Clinic's Clinical Immunoassay Lab, explains how humans can develop an allergy to the alpha-gal molecule, and he describes a new allergen antibody test that can be used to detect it. Dr. Bornhorst also reviews other tests that should be used in conjunction with alpha-gal testing to accurately identify the scope and underlying cause of the allergy.
Dr. Patel, director of Mayo Clinic's Infectious Diseases Research Laboratory, discussed the future of testing for joint and bone infections.
Nancy Wengenack, Ph.D. gives an overview of this test available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing compares to other testing approaches, and what clinical action can be taken due to the results of this testing.
In this month’s “Hot Topic,” Elitza Theel, Ph.D., talks about Mayo Clinic Laboratories’ serologic and molecular testing for the identification of infection with dengue virus. Dengue virus poses a significant public health threat worldwide. Rapid and accurate identification of the infection enables directed monitoring of patients who may be at increased risk of developing hemorrhagic fever of dengue shock syndrome.
Antimicrobial susceptibility testing determines whether these bacteria are susceptible or resistant to a particular antibiotic. Bacteria are added onto plates of solid agar, where each plate has a different and increasing concentration of antibiotic than the previous plate. The minimum inhibitory concentration (MIC) is the lowest concentration of an antimicrobial that inhibits growth of the bacteria.
Mayo Clinic Laboratories is one of the few laboratories in the country to offer two special sequencing-based tests for bacteria in its catalog. The first test is designed to help protect patients by investigating potential outbreaks of a single bacterial species or by identifying recurrent infections in an individual patient. The second has the ability to detect DNA of any bacteria to help identify the cause of an infection.